5 Biotech Stocks to Consider for Your Portfolio in 2024

Quite a few bigwigs in the biotech sector have reported results for the fourth quarter and the picture is ordinary. While results have been mixed, the outlook provided by most of these companies is encouraging, indicating bright prospects driven by new drug approvals and positive pipeline updates. The macroeconomic environment, however, remains uncertain and growth might be sluggish.Meanwhile, biotech companies are in the spotlight as pharma/biotech giants are now looking to bolster their product portfolios ...